Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy
| Autor: | Kith Pradhan, R. Alejandro Sica, Astha Thakkar, Amit Verma, Sanjay Goel, Zhu Cui, Joseph A. Sparano, Shawn Jindal, Bradley Rockwell, Stuart H. Packer, D. Yitzhak Goldstein, Akash Pradip Shah, Balazs Halmos |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.drug_class medicine.medical_treatment Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Antibodies Viral Monoclonal antibody Article Young Adult Neoplasms Internal medicine medicine Humans Seroconversion Aged Retrospective Studies Aged 80 and over biology SARS-CoV-2 business.industry Cancer Retrospective cohort study Immunotherapy Middle Aged medicine.disease Vaccination Oncology COVID-19 Nucleic Acid Testing Immunoglobulin G biology.protein Female Antibody business |
| Zdroj: | Nat Cancer |
| ISSN: | 2662-1347 |
| Popis: | Patients with cancer have been identified in several studies to be at high risk of developing severe COVID-19; however, rates of SARS-CoV-2 IgG seroconversion and its association with cancer types and anti-cancer therapy remain obscure. We conducted a retrospective cohort study in patients with cancer that underwent SARS-CoV-2 IgG testing. Two hundred and sixty-one cancer patients underwent SARS-CoV-2 IgG testing and demonstrated a high rate of seroconversion (92%). However, significantly lower seroconversion was observed in patients with hematologic malignancies (82%), patients that received anti-CD-20 antibody therapy (59%), CAR-T/cellular therapy (33%) and stem cell transplant (60%). Interestingly, all 17 patients that received immunotherapy, including 16 that received anti-PD-1/PD-L1 monoclonal antibodies, developed SARS-Cov-2 IgG antibodies (100% seroconversion). These data show differential rates of seroconversion in specific patient groups and bear importance for clinical monitoring and vaccination strategies that are being developed to mitigate the COVID-19 pandemic |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink